title: Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.
abstract: More women are living with and surviving breast cancer, because of improvements in breast cancer care. Trastuzumab (Herceptin) has significantly improved outcomes for women with HER2-positive tumours. Concerns about the cardiac effects of trastuzumab (which fundamentally differ from the permanent myocyte loss associated with anthracyclines) led to the development of cardiac guidelines for adjuvant trials, which are used to monitor patient safety in clinical practice. Clinical experience has shown that the trial protocols are not truly applicable to the breast cancer population as a whole, and exclude some women from receiving trastuzumab, even though they might benefit from treatment without long-term adverse cardiac sequelae. Consequently, five oncologists who recruited patients to trastuzumab trials, some cardiologists with whom they work, and a cardiovascular lead general practitioner reviewed the current cardiac guidelines in the light of recent safety data and their experience with adjuvant trastuzumab. The group devised recommendations that promote proactive pharmacological management of cardiac function in trastuzumab-treated patients, and that apply to all patients who are likely to receive standard cytotoxic chemotherapy. Key recommendations include: a monitoring schedule that assesses baseline and on-treatment cardiac function and potentially reduces the overall number of assessments required; intervention strategies with cardiovascular medication to improve cardiac status before, during, and after treatment; simplified rules for starting, interrupting and discontinuing trastuzumab; and a multidisciplinary approach to breast cancer care.
authors.affiliation: Department of Oncology, Royal Free and University College London Hospitals, UK. alison.jones3@uclh.org
authors.forename: A L
authors.initials: AL
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Barlow
authors.forename: P J
authors.initials: PJ
authors.lastname: Barrett-Lee
authors.forename: P A
authors.initials: PA
authors.lastname: Canney
authors.forename: I M
authors.initials: IM
authors.lastname: Gilmour
authors.forename: S D
authors.initials: SD
authors.lastname: Robb
authors.forename: C J
authors.initials: CJ
authors.lastname: Plummer
authors.forename: A M
authors.initials: AM
authors.lastname: Wardley
authors.forename: M W
authors.initials: MW
authors.lastname: Verrill
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006287:Health Planning Guidelines; D006321:Heart / Q000503:physiopathology; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control*; D006333:Heart Failure / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D000068878:Trastuzumab; D006113:United Kingdom; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab